● Recruiting

Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

Condition: Asthma · Sponsor: Chiesi Farmaceutici S.p.A.

PhasePhase 3

Planned participants554

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial INFO Chiesi Farmaceutici S.p.A. · + 39 0521 2791 · clinicaltrials_info@chiesi.com

Always discuss trial participation with your own doctor first.

Locations (2)

China-Japan Friendship Hospital	Beijing, Chaoyang District, China	Recruiting
China-Japan Friendship Hospital	Beijing, Chaoyang District, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07546981